Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: A PET study with 6-[18F]L-DOPA

European Journal of Pharmacology

Volumn 334, Issue 1, 1997, Pages 31-38

  Doudet, Doris J ^a   Chan, Grace L Y ^a   Holden, James E ^b   Pate, Brian D ^a   Morrison, K Scott ^a   Calne, Donald B ^a   Ruth, Thomas J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

6 18F l DOPA (6 18F L 3 4 dihydroxyphenylalanine); Catechol O methyltransferase inhibition; Dopamine turnover; Monoamine oxidase inhibition; PET (positron emission tomography)

Indexed keywords

6 FLUORODOPA F 18; AMINE OXIDASE (FLAVIN CONTAINING); CATECHOL METHYLTRANSFERASE; NITECAPONE; PARGYLINE; SELEGILINE; TOLCAPONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE METABOLISM; ENZYME INHIBITION; INTRAVENOUS DRUG ADMINISTRATION; MONKEY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ANIMALS; ANTIPARKINSON AGENTS; BENZOPHENONES; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; DOPAMINE; ENZYME INHIBITORS; FLUORINE RADIOISOTOPES; LEVODOPA; MACACA FASCICULARIS; MONOAMINE OXIDASE INHIBITORS; NITROPHENOLS; PENTANONES; PILOT PROJECTS; TOMOGRAPHY, EMISSION-COMPUTED; VISUAL CORTEX;

EID: 0030821842     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01157-6     Document Type: Article

References (35)

1. 18F ]6-fluorodopa with F-18 acetyl hypofluorite J. Nucl. Med. 27:1986;1462-1466.
2. Backstrom R., Honkanen E., Pippuri A., Kairisalo P., Pystynen J., Heinola K., Nissinen E., Linden I.B., Mannisto P.T., Kaakkola S., Pohto P. Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors. J. Med. Chem. 32:1990;841-846.
3. 18F ]fluoro-L-DOPA probes dopamine turnover rates in central dopaminergic structures J. Neurosci. Res. 27:1990;487-493.
4. Birkmayer, W., Riederer, P., 1984. Deprenyl prolongs the therapeutic efficacy of combined L-Dopa in Parkinson's disease. In: Hassler, R.G., Christ, J.F. (Eds.), Advances in Neurology, vol. 40. Raven Press, New York, pp. 475-481.
5. Brooks D., Salmon E.P., Mathias C.J., Quinn N., Leenders K.L., Bannister R., Marsden C.D., Frackowiak R.S.J. The relationship between locomotor disability, autonomic dysfunction and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure and Parkinson's disease, studied with PET. Brain. 113:1990;1539-1552.
6. Chan G.L.Y., Hewitt K.A., Pate B.D., Schofield P., Adam M.J., Ruth T.J. Routine determination of [F18]-L-6-fluorodopa and its metabolites in blood plasma is essential for accurate positron emission tomography studies. Life Sci. 50(4):1992;309-318.
7. Chiueh C.C., Zubowska-Grojec Z., Kirk K.L., Kopin I.J. 6-fluorocatecholamines as false adrenergic neurotransmitters. J. Pharmacol. Exp. Ther. 225:1983;529-533.
8. Cumming P., Leger G., Kuwabara H., Gjedde A. Pharmacokinetics of plasma 6-[18F]fluoro-L-3,4-dihydroxy-phenylalanine ([18F]FDOPA) in humans. J. Cereb. Blood Flow Metab. 13:1993;668-675.
9. Da Prada M., Kettler R., Keller H.H., Cesura A.M., Richards J.G., Saura Marti J., Muggli-Maniglio D., Wyss P.C., Kyburz E., Imhof R. From moclobemide to Ro 19-6327 and Ro 41-1049: The development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J. Neural Transm. 29 (Suppl.):1990;279-292.
10. Da Prada M., Borgulya J., Napolitano A., Zurcher G. Improved therapy of Parkinson's disease with tolcapone, a central and peripheral COMT inhibitor with an S-adenosyl-L-methionine-sparing effect. Clin. Neuropharmacol. 17:1994;S26-S37.
11. Doudet D.J., McLellan C.A., Carson R.E., Adams H.R., Miyake H., Aigner T.G., Finn R.T., Cohen R.M. Distribution and kinetics of 3-O-methyl-6-[F18]fluoro-L-DOPA in the rhesus monkey brain. J. Cereb. Blood Flow Metab. 11:1991;726-734.
12. Doudet D.J., Chan G.L.Y., Holden J.E., Morrison K.S., Dobko T., Wyatt R.J., Ruth T.J. Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-dopa trapping in MPTP-induced parkinsonism in monkeys. Neuropharmacology. 36:1997;363-371.
13. Elizan T.S., Yahr M.D., Moros D.A., Mendoza M.R., Pang S., Bodian C.A. Selegiline use to prevent progression of Parkinson's disease. Arch. Neurol. 46:1989;1275-1279.
14. Evans B.R., Harrop D., Heywood J., Mackintosh R.W., Moore R.W., Pate B.D., Rogers J.G., Ruth T.J., Sayre C., Sprenger H., Van Oers N., Guang Y.X. Engineering development on the aUBC-TRIUMF modified PETT VI positron emission tomograph. IEEE Trans. Nucl. Sci. NS-30:1983;707-710.
15. 18F -fluoro-L-3,4-dihydroxyphenylalanine in the primate J. Neurochem. 48:1987;1077-1082.
16. Garnett E.S., Firnau G., Nahmias C., Sood S., Belbeck L.W. Blood-brain barrier transport and cerebral utilization of dopa in living monkeys. Am. J. Physiol. 238:1980;R318-327.
17. Holden, J.E., Doudet, D.J., Endres, C.J., Chan, G.L.Y., Morrison, K.S., Vingerhoets, F.J.G., Snow, B.J., Pate, B.D., Sossi, V., Buckley, K.R., Ruth, T.J., 1997. Extended graphical analysis of 6-fluoro-L-dopa trapping: Effect of inhibition of catechol-O-methyltransferase on the rate of reversibility. J. Nucl. Med., in press.
18. Ishikawa T., Dhawan V., Chaly T., Robeson W., Belakhlef A., Mandel F., Dahl R., Margouleff C., Eidelberg D. Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: Effect of the plasma 3-O-methyldopa fraction on data analysis. J. Cereb. Blood Flow Metab. 16:1996;854-863.
19. Kaakkola S., Gordin A., Jarvinen M., Wikberg T., Schultz E., Nissinen E., Pentikainen P.J., Rita H. Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers. Clin. Neuropharmacol. 13:1990;436-447.
20. Kofman O.S. Deprenyl: Protective vs. symptomatic effect. Can. J. Neurol. Sci. 18:1991;83-86.
21. Laihinen A., Rinne J.O., Rinne U.K., Haaparanta M., Ruotsalainen U., Bergman J., Solin O. [F18]-6-fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462). Neurology. 42:1992;199-203.
22. Linden I.B., Nissinen E., Etemadzadeh E., Kaakkola S., Mannisto P.T., Pohto P. Favorable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease. J. Pharmacol. Exp. Ther. 247:1988;289-293.
23. Maj J., Rogoz Z., Skuza G., Sowinska H., Superata J. Behavioral and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson's disease. J. Neural Transm. Parkinson's Dis. Dementia Sect. 2:1990;101-112.
24. Mannisto P.T., Kaakkola S. Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol. Toxicol. 66:1990;317-323.
25. Martin W.R.W., Palmer M.R., Patlak C.S., Calne D.B. Nigrostriatal function in humans studied with positron emission tomography. Ann. Neurol. 26:1989;535-542.
26. Melega W.P., Hoffman J.M., Luxen A., Nissenson C.H.K., Phelps M.E., Barrio J.R. The effects of carbidopa in the metabolism of 6-[F18]fluoro-L-dopa in rats, monkeys, and humans. Life Sci. 47:1990;149-157.
27. Melega W.P., Luxen A., Perlmutter M., Nissenson C.H.K., Phelps M.E., Barrio J.R. Comparative in vivo metabolism of 6-[18F]fluoro-L-dopa and [3H]L-dopa in rats. Biochem. Pharmacol. 39:1990;1853-1860.
28. Myllyla V.V., Sotaniemi K.A., Vuorinen J.A. Selegiline as a primary treatment of Parkinson's disease. Acta Neurol Scand. 84 (Suppl.):1991;70-72.
29. Napolitano A., Zurcher G., Da Prada M. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-DOPA and dopamine in rats. Eur. J. Pharmacol. 273:1995;215-221.
30. Nomoto M., Fukuda T. A selective MAO-B inhibitor Ro19-6327 potentiates the effects of levodopa on parkinsonism induced by MPTP in the common marmoset. Neuropharmacology. 32:1993;473-477.
31. Patlak C.S., Blasberg R.G. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J. Cereb. Blood Flow Metab. 5:1985;584-590.
32. Ruottinen H., Rinne J.O., Ruotsalainen U., Bergman J., Oikonen V., Haaparanta M., Solin O., Laihinen A., Rinne U.K. Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease. J. Neural Transm. 10:1995;91-106.
33. Sawle G.V., Burn D.J., Morrish P.K., Lammertsma A.A., Snow B.J., Luthra S.K., Osman S., Brooks D.J. The effect of entacapone (OR-611) on brain [18-F]-6-L-fluorodopa metabolism: Implications for levodopa therapy of Parkinson's disease. Neurology. 44:1994;1292-1297.
34. Sossi V., Buckley K.R., Snow B.J., Holden J.E., Morrison K.S., Pate B.D., Ruth T.J. Recovery of the human striatal signal in a slice oriented positron emission tomograph. J. Nucl. Med. 34:1993;481-487.
35. Yu P.H. Pharmacological and clinical implications of MAO-B inhibitors. Gen. Pharmac. 25:1994;1527-1539.